ID   GLC-4/AM3x
AC   CVCL_Y299
SY   GLC4/AM3x
DR   Wikidata; Q54835914
RX   PubMed=8980384;
CC   Doubling time: 18.6 hours (PubMed=8980384).
CC   Selected for resistance to: ChEBI; CHEBI_2687; Amsacrine.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0279 ! GLC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 19-12-24; Version: 12
//
RX   PubMed=8980384; DOI=10.1038/bjc.1996.647; PMCID=PMC2074800;
RA   Withoff S., de Vries E.G.E., Keith W.N., Nienhuis E.F.,
RA   van der Graaf W.T.A., Uges D.R.A., Mulder N.H.;
RT   "Differential expression of DNA topoisomerase II alpha and -beta in
RT   P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines
RT   of the human SCLC cell line GLC4.";
RL   Br. J. Cancer 74:1869-1876(1996).
//